Agree that Growth for the stock depends on management’s ability to secure more distribution partnerships. Next Science has secured three relevant partners to distribute their products: 3M, Zimmer Biomet, and Grace Medical with each being leaders in their field. The risk will be the Upcoming Clinical trial read-outs if the results are positive, the uptake of their products will increase and vice versa. The pipeline of products will also help revenue moving forward when they come to market.
Like most growth stocks retreating, the price got ahead of itself and I now view this as an opportunity.
Charts NXS, page-517
Add NXS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.0¢ |
Change
0.005(3.45%) |
Mkt cap ! $43.82M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 16.0¢ | 14.0¢ | $58.48K | 396.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5028 | 14.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.0¢ | 37881 | 1 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| NXS (ASX) Chart |